Josée Rose

1 month ago | wsj.com | Josée Rose

Adtalem Global Education ATGE 2.24%increase; green up pointing triangle Chief Executive Steve Beard is looking at 2025 as an opportunity for growth, despite political and economic uncertainty. The head of the healthcare education company said Adtalem is looking to invest in the organic growth of its education business, particularly in nursing, its largest area of focus. “We think we already have the best mouse trap out there,” he said. “I’d rather grow that than buy someone else’s mouse trap.”

Oct 29, 2024 | tradingview.com | Josée Rose

Stryker Raises FY24 Adjusted Guidance on Strong 3Q ResultsSYKStryker raised its full year adjusted earnings guidance and reported a third-quarter profit that rose on higher sales. The Portage, Mich.-based, medical technology company on Tuesday said earnings were $2.16 a share, and net sales rose 11.9% to $5.5 billion, as organic net sales rose 11.5%.

Oct 29, 2024 | morningstar.com | Josée Rose

By Josée Rose Stryker raised its full year adjusted earnings guidance and reported a third-quarter profit that rose on higher sales. The Portage, Mich.-based, medical technology company on Tuesday said earnings were $2.16 a share, and net sales rose 11.9% to $5.5 billion, as organic net sales rose 11.5%. MedSurg and Neurotechnology net sales came in at $3.2 billion, up 12.8% from a year earlier, while Orthopaedics and Spine net sales of $2.3 billion increased 10.7% year-over-year.

Sep 12, 2024 | businessinsider.es | Josée Rose |Alexandra York

Muchos solicitantes de empleo de la generación Z han empezado a preguntar por la conciliación de la vida laboral y familiar en las entrevistas de trabajo. Los directivos de recursos humanos han empezado a tomar nota y a tener en cuenta las nuevas expectativas laborales que pasan por una mayor flexibilidad y conciliación. La mano de obra actual no se parece en nada a ninguna que hayamos visto antes, a pesar de que ahora mismo en ella conviven varias generaciones.

Aug 1, 2024 | tradingview.com | Josée Rose

Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug DevelopmentVIRVir Biotechnology is restructuring to focus on its clinical-stage pipeline and is cutting about 140 jobs. The clinical stage biopharmaceutical company is phasing out programs in influenza, Covid-19 and T-cell based viral vector. This will result in a workforce reduction of about 25%. Vir expects to have about 435 employees by the end of 2024, down about 200 from its peak headcount in 2023.